Table 3.
Group | Adults (all patients) | Adults (Study A2401) | Children | |||
---|---|---|---|---|---|---|
No./total (%) | 95% CI | No./total (%) | 95% CI | No./total (%) | 95% CI | |
mITT population | ||||||
Non-PCR corrected | 497/599 (83.0) | 79.7–85.9 | 120/162 (74.1) | 66.6–80.6 | 743/863 (86.1) | 83.6–88.3 |
PCR corrected† | 499/598 (83.4) | 80.2–86.3 | 120/162 (74.1)‡ | 66.6–80.6 | 798/854 (93.4) | 91.6–95.0 |
Evaluable patients | ||||||
Non-PCR corrected | 494/511‡ (96.7) | 94.7–98.1 | 119/124 (96.0) | 90.8–98.7 | 737/823 (89.6) | 87.3–91.6 |
PCR corrected† | 495/510§¶ (97.1) | 95.2–98.3 | 119/124 (96.0) | 90.8–98.7 | 792/814 (97.3) | 95.9–98.3 |
CI = confidence interval; mITT = modified intent-to-treat; PCR = polymerase chain reaction.
PCR analysis was not performed in study A2401.
Two patients were excluded from this analysis after starting antimalarial treatments before day 28 (for reasons other than rescue medication).
Last observation carried forward: 147 of 162 (90.7%).
One patient was excluded because of a new infection that started before day 28.